Related Experiment Video
Updated: Aug 18, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
COX-2: a molecular target for colorectal cancer prevention
Joanne R Brown1, Raymond N DuBois
1The Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.
Abstract:
Cyclooxygenase (COX), a key enzyme in the prostanoid biosynthetic pathway, has received considerable attention due to its role in human cancers. Observational and randomized controlled studies in many different population cohorts and settings have demonstrated protective effects of nonsteroidal anti-inflammatory drugs (NSAIDs; the inhibitors of COX activity) for colorectal cancers (CRCs). COX-2, the inducible isoform of cyclooxygenase, is overexpressed in early and advanced CRC tissues, which portends a poor prognosis. Experimental studies have thus identified important mechanisms and pathways by which COX-2 plays an important role in carcinogenesis. Selective COX-2 inhibitors have been approved for use as adjunctive therapy for patients with familial polyposis. The role of COX-2 inhibitors is currently being evaluated for use in wider populations.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) show protective effects against colorectal cancers (CRCs). Specifically, cyclooxygenase-2 (COX-2) inhibitors are being evaluated for broader use due to their role in cancer progression.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Cyclooxygenase (COX) is a key enzyme in prostanoid biosynthesis and is implicated in human cancers.
- Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit COX activity, have demonstrated protective effects against colorectal cancers (CRCs).
- The inducible COX-2 isoform is overexpressed in CRC tissues, correlating with a poor prognosis.
Purpose of the Study:
- To investigate the role of cyclooxygenase (COX) enzymes, particularly COX-2, in the development and progression of colorectal cancers (CRCs).
- To evaluate the therapeutic potential of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors in CRC prevention and treatment.
Main Methods:
- Review of observational and randomized controlled studies on NSAIDs and CRC.
- Analysis of experimental studies elucidating the mechanisms of COX-2 in carcinogenesis.
- Examination of clinical trial data for selective COX-2 inhibitors in familial polyposis and broader populations.
Main Results:
- Numerous studies confirm the protective effects of NSAIDs against CRC development.
- Overexpression of COX-2 in CRC tissues is a significant negative prognostic indicator.
- Experimental evidence highlights COX-2's crucial role in cancer-related pathways.
Conclusions:
- NSAIDs, particularly COX-2 inhibitors, hold significant promise for colorectal cancer prevention and treatment.
- Selective COX-2 inhibitors are approved for familial polyposis and are under investigation for wider clinical application.
- Targeting COX-2 represents a viable strategy in the ongoing fight against colorectal cancer.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Prevention
Some...
Cancer Prevention
Some...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

